Skip to main content
. Author manuscript; available in PMC: 2014 Mar 18.
Published in final edited form as: J Neurosci Res. 2009 Dec;87(16):3535–3545. doi: 10.1002/jnr.22170

Fig. 5.

Fig. 5

Effects of another O-GlcNAcase inhibitor, Stz, on NECs. A: The increase of O-GlcNAc in NECs treated with Stz (10 mM) for 6 hr was examined by immunocytochemistry. Nuclei and O-GlcNAc were stained with Hoechst 33258 and CTC110.6 anti-O-GlcNAc antibody, respectively. B: Dose-dependent increases of O-GlcNAc in NECs treated with Stz for 6 hr were examined by Western blot analysis. C: The NEC number reduction by treatment with Stz for 0–4 days was traced with the WST-8 assay. D: The NEC number reduction by treatment with Stz for 4 days was compared with that of an MEK inhibitor, U0126 (4 μM). E: The activation of caspase-3 in NECs treated with or without Stz (10 mM) for 8 hr was analyzed by Western blot. F: Caspase-3 activity in NECs treated with or without Stz (10 mM) for 8 hr was assayed by measuring the absorbance of p-nitroanilide after cleavage from Asp-Glu-Val-Asp-pNA by caspase-3 at a wavelength of 405 nm.